Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
kidney save search
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
Published: 2024-04-11 (Crawled : 00:00) - biospace.com/
NTRA S | $84.22 -3.51% 730K
|
Health Services
|
| O: -0.36%
H: 0.0%
C: 0.0%
kidney publication study
Diabetic Kidney Disease Market to Witness Upsurge in Growth at a CAGR of ~6.5% by 2034 | DelveInsight
Published: 2024-04-01 (Crawled : 22:00) - prnewswire.com
PKX | News | $70.665 0.81% 13K
|
Non-Energy Minerals
|
| O: -0.77%
H: 0.0%
C: -0.85%
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: -0.77%
H: 0.8%
C: 0.74%
disease kidney growth market diabetic
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
VRTX | News | $395.42 0.49% 290K
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: 0.0%
vx-147 disease kidney treatment trial
FDA Approves Treatments for Anemia in Chronic Kidney Disease, Hepatitis
Published: 2024-03-29 (Crawled : 19:00) - biospace.com/
SNY | News | $46.34 2.09% 620K
|
Health Technology
| Email alert
Add to watchlist
ABT | News | $107.24 1.87% 2M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
| Email alert
Add to watchlist
PRGO | $30.22 0.94% 140K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
fda hepatitis kidney anemia
Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients
Published: 2024-03-28 (Crawled : 07:00) - prnewswire.com
TVTX | $5.745 -0.95% 310K
|
Health Technology
|
| O: 0.91%
H: 3.1%
C: -0.39%
AKBA | $1.345 -3.24% 830K
|
Health Technology
|
| O: 10.27%
H: 0.4%
C: -25.91%
vafseo fda disease kidney anemia approved treatment
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
Published: 2024-03-28 (Crawled : 01:00) - prnewswire.com
AKBA | $1.345 -3.24% 830K
|
Health Technology
|
| O: 10.27%
H: 0.4%
C: -25.91%
vafseo fda disease kidney anemia approval treatment dialysis
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2024-03-21 (Crawled : 21:00) - biospace.com/
VRTX | News | $395.42 0.49% 290K
|
Health Technology
|
| O: 0.85%
H: 0.88%
C: 0.02%
vx-407 fda drug disease kidney treatment clearance application
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
Published: 2024-03-21 (Crawled : 14:30) - globenewswire.com
ELDN | $1.91 -4.02% 200K
|
Manufacturing
|
| O: -1.78%
H: 15.66%
C: 13.25%
kidney pharmaceuticals
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
Published: 2024-03-18 (Crawled : 12:00) - globenewswire.com
ZVSA | $0.616 -1.6% 110K
|
|
| O: 7.64%
H: 21.41%
C: 1.07%
disease kidney cholesterol approval trial therapeutics diabetic
SOPHiA GENETICS and The French Kidney Cancer Research Network (UroCCR) Publish Results from Multiyear Collaboration
Published: 2024-03-15 (Crawled : 10:00) - prnewswire.com
SOPH | $4.81 0.21% 6.3K
|
|
| O: 3.8%
H: 7.84%
C: 2.06%
kidney cancer research collaboration network results
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
Published: 2024-03-14 (Crawled : 11:00) - globenewswire.com
RNLX | $0.785 17K
|
Technology Services
|
| O: 3.23%
H: 13.12%
C: 5.78%
disease kidney
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
RGLS | $2.135 -3.83% 100K
|
Health Technology
|
| O: 68.84%
H: 62.66%
C: 1.29%
rgls8429 disease kidney positive treatment topline trial therapeutics
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
LXRX | News | $1.66 1.84% 810K
|
Health Technology
|
| O: 0.36%
H: 0.32%
C: -10.64%
disease kidney control treatment diabetes study
SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024
Published: 2024-03-11 (Crawled : 20:00) - globenewswire.com
ICU A | $0.44 -18.52% 3.3M
|
|
| O: 1.11%
H: 19.57%
C: 9.78%
device kidney symposium
Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial
Published: 2024-03-05 (Crawled : 10:00) - globenewswire.com
NVO | $123.01 0.21% 2.6M
|
Health Technology
|
| O: -1.33%
H: 0.46%
C: -1.27%
disease kidney risk trial diabetes flow
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients
Published: 2024-03-04 (Crawled : 12:00) - globenewswire.com
UNCY | $1.09 100K
|
Professional, Scientific, and T...
|
| O: 1.25%
H: 2.46%
C: -8.02%
uni-494 drug kidney granted food designation therapeutics
FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury
Published: 2024-02-22 (Crawled : 13:00) - globenewswire.com
ICU A | $0.44 -18.52% 3.3M
|
|
| O: 17.59%
H: 0.7%
C: -34.9%
fda device kidney approval grants
Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting
Published: 2024-02-14 (Crawled : 12:00) - globenewswire.com
UNCY | $1.09 100K
|
Professional, Scientific, and T...
|
| O: 3.81%
H: 7.34%
C: 6.42%
kidney spring meeting therapeutics
Kidney Transplantation Therapeutics Market 2023; USD 643.15 million Growth Expected between 2023 and 2028, Rising prevalence of CKD and renal impairments to boost growth - Technavio
Published: 2024-01-29 (Crawled : 18:00) - prnewswire.com
ALPMF | $9.17 16K
|
Health Technology
|
| O: 1.76%
H: 0.0%
C: 0.0%
GLAXF | $20.2 510
|
Health Technology
|
| O: 2.93%
H: 0.0%
C: -1.15%
ALPMY | $9.47 520K
|
Manufacturing
|
| O: -3.53%
H: 3.49%
C: 3.4%
NVS | $93.815 1.35% 410K
|
Health Technology
|
| O: -0.59%
H: 0.49%
C: 0.41%
GSK | $39.605 0.85% 790K
|
Health Technology
|
| O: 0.26%
H: 0.13%
C: -0.18%
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 0.19%
H: 0.46%
C: 0.43%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
kidney renal expected million therapeutics growth market
New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease
Published: 2024-01-10 (Crawled : 12:00) - globenewswire.com
RNLX | $0.785 17K
|
Technology Services
|
| O: -7.2%
H: 1.58%
C: -8.34%
disease kidney
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.054 50.0% 290M
|
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
NVFY | $2.71 28.44% 31M
|
Consumer Durables
ZCMD | $1.86 28.28% 29M
|
Commercial Services
RWOD | $10.08 26.05% 5.6M
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
TPET | $0.4001 22.02% 35M
|
n/a
SRFM 4 | $0.6 21.29% 850K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.